Alitretinoin in the Treatment of Chronic Hand Eczema
Open Label Treatment of Patients With Chronic Hand Dermatitis Who Have Participated in a Previous Clinical Trial Involving Oral Alitretinoin
Sponsor: Basilea Pharmaceutica
This PHASE3 trial investigates Eczema and is currently completed. Basilea Pharmaceutica leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jun 2023 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
May 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Basilea Pharmaceutica
For direct contact, visit the study record on ClinicalTrials.gov .